Navigation Links
French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
Date:12/11/2012

CAMBRIDGE, England, Dec. 11, 2012 /PRNewswire/ -- The Lycotec team has recently started to publish its findings on the French cheese, Roquefort, in "Could cheese be the missing piece in the French paradox puzzle?" Unexpected anti-inflammatory factors discovered in this blue-vein cheese could lead to the development of a new generation of pharmaceuticals and future cosmetic products.

In this first publication, the authors Dr. Ivan Petyaev and Dr. Yuriy Bashmakov suggest that regular consumption of Roquefort, Camembert and other moulded fermented cheeses could be the answer to some of today's key health problems. Despite a diet high in saturated fats, France has been known to have the lowest rate of cardiovascular mortality. Today, the real secret to this lifestyle has been revealed. Eat more mouldy cheese!

Extensive laboratory and clinical validation by the Lycotec doctors and scientists have demonstrated that these anti-inflammatory factors, which occur during the ripening of the cheese, have unique properties which work best in acidic environments. The most notable two environments affected by these smelly cheeses include the stomach lining and skin surface.

In fact, the anti-inflammatory factors found in these cheeses could be extracted and used independently or as a part of today's pharmaceutical or beauty products. Moreover, there is a growing consensus that sub-clinical inflammation is behind many aging processes, from the loss of skeletal muscles and cellulite to metabolic, cardiovascular and cerebrovascular diseases.

The Lycotec Team urges pharmaceutical and beauty product companies to take a look at this new publication for future product ideas and partnerships, without the mouldy smell.

About the Lycotec Team:

Based in Cambridge, Lycotec focuses on the development and commercialisation of its proprietary bio-medical technologies for pharmaceutical, nutraceutical and functional food industries.

For more information please contact info(at)lycotec(dot)com

Media Contact:
Ivan Petyaev
petyaev(at)lycotec(dot)com
07921363740
Lycotec
http://www.lycotec.com  

 


'/>"/>
SOURCE Lycotec
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. French Government Agrees to Fund Study of the PneumRx RePneu Lung Volume Reduction Coil
2. Pycnogenol® (French Maritime Pine Bark Extract) Shown To Improve Endothelial Function And Reduce Oxidative Stress In New Clinical Trial
3. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
4. Cardinal Health Honored With Best Employers for Healthy Lifestyles Award by National Business Group on Health
5. Data Underscore Promise of Satori Pharmaceuticals Gamma-Secretase Modulator Program in Treatment of Alzheimers Disease
6. Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimers Disease
7. Total Therapeutic Management, Inc. invites directors of quality improvement to learn secrets of provider engagement strategies
8. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
9. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
10. Express Scripts Publishes Inaugural Drug Trend Quarterly, Provides First Comprehensive Overview of U.S. Prescription Drug Spending for 2012
11. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):